Table 1.
Overview of human microRNAs with altered expression in NAFLD, NASH and cirrhosis.
| microRNA | Regulation in NAFLD | Regulation in NASH | Regulation in fibrosis/cirrhosis | References |
|---|---|---|---|---|
| miR-103-2∗ | Upregulated | – | – | Soronen et al., 2016 |
| miR-106b∗ | Upregulated | – | – | Soronen et al., 2016 |
| miR-122 | Upregulated in simple steatosis, else downregulated | Downregulated | – | Cheung et al., 2008 |
| Latorre et al., 2017 | ||||
| Miyaaki et al., 2014 | ||||
| Pirola et al., 2015 | ||||
| miR-1282 | Upregulated | – | – | Soronen et al., 2016 |
| miR-139-5p | Downregulated | – | – | Latorre et al., 2017 |
| miR-146b | – | Upregulated | – | Cheung et al., 2008 |
| miR-146b-5p | Upregulated | – | – | Latorre et al., 2017 |
| miR-150 | – | – | Upregulated | Leti et al., 2015 |
| miR-17 | – | – | Downregulated | Leti et al., 2015 |
| miR-182 | – | – | Upregulated | Leti et al., 2015 |
| miR-183 | – | – | Upregulated | Leti et al., 2015 |
| mIR-198 | – | Downregulated | – | Cheung et al., 2008 |
| miR-200a | – | Upregulated | – | Cheung et al., 2008 |
| mIR-21 | – | Upregulated | Upregulated | Cheung et al., 2008 |
| Dattaroy et al., 2015 | ||||
| Loyer et al., 2016 | ||||
| Rodrigues et al., 2017 | ||||
| Zhang et al., 2013 | ||||
| miR-219a | – | – | Downregulated | Leti et al., 2015 |
| miR-222 | – | Upregulated | – | Cheung et al., 2008 |
| miR-224 | – | -Upregulated | Upregulated | Cheung et al., 2008 |
| Leti et al., 2015 | ||||
| miR-26a | Downregulated | – | – | Xu et al., 2020 |
| miR-301a-3p | Upregulateda | Upregulateda | Upregulateda | Guo et al., 2016 |
| miR-30b-5p | Downregulated | – | – | Latorre et al., 2017 |
| miR-31 | – | – | Upregulated | Leti et al., 2015 |
| miR-34a | Upregulated | Upregulated | – | Castro et al., 2013 |
| Cheung et al., 2008 | ||||
| Liu et al., 2018 | ||||
| miR-34a-5p | Upregulateda | Upregulateda | Upregulated | Guo et al., 2016 |
| miR-3663-5p | Upregulated | – | – | Soronen et al., 2016 |
| miR-375 | Downregulateda | Downregulateda | Downregulatedb | Guo et al., 2016 |
| miR-378 | Upregulated | Upregulated | – | Zhang, Duan et al., 2019 |
| Zhang, Hu et al., 2019 | ||||
| miR-378i | – | – | Downregulated | Leti et al., 2015 |
| miR-3924 | Upregulated | – | – | Soronen et al., 2016 |
| miR-422a | Downregulated | – | – | Latorre et al., 2017 |
| miR-576-5p | Upregulated | – | – | Soronen et al., 2016 |
| miR-590 | – | – | Downregulated | Leti et al., 2015 |
| miR-601 | – | Downregulated | – | Cheung et al., 2008 |
| miR-617 | – | Downregulated | – | Cheung et al., 2008 |
| miR-641 | – | Downregulated | – | Cheung et al., 2008 |
| miR-765 | – | Downregulated | – | Cheung et al., 2008 |
| miR-892a | Upregulated | – | – | Soronen et al., 2016 |
| miRPlus-I137∗ | Upregulated | – | – | Soronen et al., 2016 |
a
Found by trend analysis to gradually increase or decrease with disease progression from the non-steatotic state through NAFL and NASH to cirrhosis.
b
Found to be significantly downregulated in cirrhosis vs. NASH by the differential expression analysis and found to gradually decrease from early NAFLD towards the cirrhotic state by the trend analysis.